NCT04766177 Role of Bumetanide in Treatment of Autism
| NCT ID | NCT04766177 |
| Status | Recruiting |
| Phase | Phase 3 |
| Sponsor | Sherief Abd-Elsalam |
| Condition | Autism |
| Study Type | INTERVENTIONAL |
| Enrollment | 80 participants |
| Start Date | 2021-01-01 |
| Primary Completion | 2030-12-01 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
Phase 3 trials are large pivotal studies comparing the treatment to current standard of care or placebo. Your participation directly contributes to the evidence needed for regulatory approval.
This trial targets 80 participants in total. It began in 2021-01-01 with a primary completion date of 2030-12-01.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
Role of bumetanide in Autism
Eligibility Criteria
Inclusion Criteria: 1. All patients with ASD diagnosed by CARS rating Scale⩾30. 2. Age of patients range between (3-12) years. Exclusion Criteria: * Patients with ASD associated with neurological antecedents (including epilepsies and febrile seizures), hepatic, renal dysfunction or electrocardiogram abnormalities and syndromatic children(Rett).
Contact & Investigator
Osama Elagamy, Prof
PRINCIPAL INVESTIGATOR
Pediatrics Department- Kafr-Elsheikh University
Frequently Asked Questions
Who can join the NCT04766177 clinical trial?
This trial is open to participants of all sexes, aged 3 Years or older, up to 12 Years, studying Autism. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
What phase is the NCT04766177 trial and what does that mean for participants?
Phase 3 trials are large-scale studies comparing the new treatment to existing standards of care or a placebo. They provide the evidence needed for regulatory approval. This trial targets 80 participants.
Is NCT04766177 currently recruiting?
Yes, NCT04766177 is actively recruiting participants. Contact the research team at sheriefabdelsalam@yahoo.com for enrollment information.
Where is the NCT04766177 trial being conducted?
This trial is being conducted at Tanta, Egypt.
Who is sponsoring the NCT04766177 clinical trial?
NCT04766177 is sponsored by Sherief Abd-Elsalam. The principal investigator is Osama Elagamy, Prof at Pediatrics Department- Kafr-Elsheikh University. The trial plans to enroll 80 participants.